Want to see ISRG full AI Analyst Report?
ISRG Stock Chart & Stats
$337.50
$13.91(4.12%)
At close: 4:00 PM EDT
$337.50
$13.91(4.12%)
Day’s Range― - ―
52-Week Range$328.57 - $603.88
Previous CloseN/A
Volume15.48K
Average Volume (3M)3.36M
Market Cap
$124.82B
Enterprise Value$136.97K
Total Cash (Recent Filing)$5.22B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)39.9
Beta1.12
Next Earnings
Oct 20, 2026EPS Estimate
2.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.85
Shares Outstanding353,278,050
10 Day Avg. Volume5,263,122
30 Day Avg. Volume3,361,781
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)11.34
Price to Sales (P/S)20.08
P/FCF Ratio81.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$487.55Price Target Upside44.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)10.8
Revenue Forecast (FY)$11.76B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Dominance From Installed BaseIntuitive’s razor‑and‑blades model yields high recurring revenue (85% of sales), driven by instruments, accessories and service per installed system. This creates predictable, high‑margin cash flow supporting reinvestment, R&D and durable earnings even if system placements fluctuate.
Conservative, Low‑leverage Balance SheetNear‑zero leverage and a growing equity base give Intuitive financial flexibility to fund R&D, support multi‑year product rollouts, and return capital via buybacks without stressing liquidity. Strong ROE progression signals improving capital efficiency and resilience through funding cycles.
Robust Free Cash Flow And Cash ConversionSizable and improving free cash flow provides durable internal funding for product development, clinical studies and commercialization. High cash conversion cushions volatility in working capital and supports sustained investment and shareholder returns without relying on external financing.
Bears Say
Visible Deceleration In Revenue And Procedure GrowthGrowth has moderated versus the high post‑2021 comps, reducing the automatic expansion of instrument/service volumes per installed base. Sustained slower procedure growth would constrain long‑run recurring revenue expansion and limit margin and earnings leverage over the medium term.
China Tender Activity And Pricing PressurePersistent tender weakness, local competition and regulatory pricing dynamics in China create a structural ceiling on system placements and I&A pricing in a major growth market. Delays in clearance for new platforms (da Vinci 5) exacerbate the region's longer‑term revenue uncertainty.
Extended‑use Instrument Program Introduces Recurring Revenue RiskA move to extended‑use instruments could reduce per‑procedure instrument sales and recurring revenue over time. The unquantified magnitude creates structural forecasting risk for I&A revenue and complicates assessment of future margin sustainability and cash generation from installed systems.
Intuitive Surgical News
ISRG FAQ
What was Intuitive Surgical’s price range in the past 12 months?
Intuitive Surgical lowest stock price was $328.57 and its highest was $603.88 in the past 12 months.
What is Intuitive Surgical’s market cap?
Intuitive Surgical’s market cap is $124.82B.
When is Intuitive Surgical’s upcoming earnings report date?
Intuitive Surgical’s upcoming earnings report date is Oct 20, 2026 which is in 76 days.
How were Intuitive Surgical’s earnings last quarter?
Intuitive Surgical released its earnings results on Jul 16, 2026. The company reported $2.8 earnings per share for the quarter, beating the consensus estimate of $2.511 by $0.289.
Is Intuitive Surgical overvalued?
According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued.
Does Intuitive Surgical pay dividends?
Intuitive Surgical does not currently pay dividends.
What is Intuitive Surgical’s EPS estimate?
Intuitive Surgical’s EPS estimate is 2.64.
How many shares outstanding does Intuitive Surgical have?
Intuitive Surgical has 353,278,050 shares outstanding.
What happened to Intuitive Surgical’s price movement after its last earnings report?
Intuitive Surgical reported an EPS of $2.8 in its last earnings report, beating expectations of $2.511. Following the earnings report the stock price went down -14.145%.
Which hedge fund is a major shareholder of Intuitive Surgical?
Currently, no hedge funds are holding shares in ISRG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intuitive Surgical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$487.55 (44.46% Upside)
$487.55 (44.46% Upside)
Blogger Sentiment
Bullish
ISRG Sentiment 95%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 83.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.54%
Trailing 12-Months
Company Description
Intuitive Surgical
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
ISRG Company Deck
ISRG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: robust revenue (+19%), strong profitability (42% non-GAAP operating margin), healthy procedure growth (total +16%) and capital placements (468 da Vinci systems), plus strong cash flow. The company also highlighted meaningful product progress (da Vinci 5 updates, SP and XiR momentum, ION adoption) and clinical evidence supporting adoption. Key risks were noted but were mostly market- and policy-driven (U.S. patient coverage dynamics, China tender and pricing pressure), some procedure-mix headwinds (bariatrics) and an unquantified impact from the extended-use instrument program. Overall, the positive metrics and growth drivers materially outweigh the challenges discussed.View all ISRG earnings summariesISRG Revenue Breakdown
67.72% U.S.
32.28% Outside of U.S
ISRG Stock 12 Month Forecast
Average Price Target
$487.55
▲(44.46% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
21.99% Mutual Funds
4.99% Other Institutional Investors
44.94% Public Companies and Individual Investors